Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2020

01-12-2020 | Breast Cancer | Correction

Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

Authors: Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman, Einav Nili Gal-Yam

Published in: Breast Cancer Research | Issue 1/2020

Login to get access

Excerpt

Correction to: Breast Cancer Res …
Literature
1.
Metadata
Title
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Authors
Adi Zundelevich
Maya Dadiani
Smadar Kahana-Edwin
Amit Itay
Tal Sella
Moran Gadot
Karen Cesarkas
Sarit Farage-Barhom
Efrat Glick Saar
Eran Eyal
Nitzan Kol
Anya Pavlovski
Nora Balint-Lahat
Daniela Dick-Necula
Iris Barshack
Bella Kaufman
Einav Nili Gal-Yam
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2020
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-020-01265-y

Other articles of this Issue 1/2020

Breast Cancer Research 1/2020 Go to the issue

Review

Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field

Research article

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

Correction

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis

Research article

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Research article

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer

Research article

In utero estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits